Trial · NCT07076121
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1) | Up to 3 years after last participant is randomized | Defined as the time between the randomization date and the date of progressive disease (PD) or death from any cause (whichever occurs first) |
| Primary | Overall Survival (OS) | Up to 3 years after last participant is randomized | Defined as the time from the randomization date to the date of death from any cause |
| Secondary | Objective Response (OR) as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | |
| Secondary | Duration of Response (DOR) as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | Defined as the time between the date of the first documentation of objective tumor response (complete response (CR) or partial response (PR)) and the date of disease progression or to death from any cause (whichever occurs first) |
| Secondary | Time to Objective Response (TTOR) as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | Defined as the time between randomization to the date of the first documentation of objective tumor response |
| Secondary | Disease control as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized | Defined as the best overall response (BOR) of confirmed CR, PR, or stable disease (SD) |
| Secondary | Number of participants with treatment-related adverse events (TRAEs) | Up to 28 days after the last drug administration | |
| Secondary | Number of participants with all-cause treatment-emergent adverse events (TEAEs) | Up to 28 days after the last drug administration | |
| Secondary | Number of participants with treatment-emergent serious adverse events (TESAEs) | Up to 28 days after the last drug administration | |
| Secondary | Number of participants with TEAEs leading to dose interruption, reduction, or discontinuation | Up to 28 days after the last drug administration | |
| Secondary | Number of participants with laboratory abnormalities | Up to 28 days after the last drug administration | |
| Secondary | PFS as assessed by RECIST v1.1 | Up to 3 years after last participant is randomized |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07076121/registered